PRDM2 and cancer: Specifically, PRDM2 gene is often target of aberrant DNA methylation and frameshift mutations in CRC; besides, most of the identified PRDM2 mutations were enriched in cancers exhibiting MSI [1, 5, 8–11, 46, 47].